We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $1.92B
1-Year Est. Return 85.52%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$1.18B
AUM Growth
-$112M
Cap. Flow
-$159M
Cap. Flow %
-13.49%
Top 10 Hldgs %
34.43%
Holding
372
New
125
Increased
6
Reduced
44
Closed
64

Top Buys

Rank Stock Value
1
MBC icon
MasterBrand
MBC
+$33.6M
2
NE icon
Noble Corp
NE
+$30.1M
3
COF icon
Capital One
COF
+$17.7M
4
LEN.B icon
Lennar Class B
LEN.B
+$15.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$9.28M

Sector Composition

Rank Sector Weight
1 Financials 33.32%
2 Healthcare 19.05%
3 Consumer Discretionary 8.98%
4 Energy 6.58%
5 Materials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WLFC icon
151
Willis Lease Finance
WLFC
$1.64B
$206K 0.02%
+10,458
New +$156K
SMHI icon
152
SEACOR Marine Holdings
SMHI
$257M
$206K 0.02%
+22,436
New +$174K
ALDX icon
153
Aldeyra Therapeutics
ALDX
$97.1M
$205K 0.02%
29,519
-670,481
-96% -$3.83M
COFS icon
154
Choiceone Financial
COFS
$511M
$205K 0.02%
+7,055
New +$165K
RYTM icon
155
Rhythm Pharmaceuticals
RYTM
$7.43B
$203K 0.02%
+6,960
New +$179K
URGN icon
156
UroGen Pharma
URGN
$2.23B
$200K 0.02%
+22,604
New +$214K
ORIC icon
157
Oric Pharmaceuticals
ORIC
$1.36B
$199K 0.02%
+33,800
New +$114K
AGIL
158
DELISTED
AgileThought Inc
AGIL
$199K 0.02%
+47,273
New +$197K
ALLK
159
DELISTED
Allakos
ALLK
$198K 0.02%
+23,464
New +$163K
RAIN
160
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$196K 0.02%
+24,512
New +$154K
PSTX
161
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$196K 0.02%
+36,966
New +$169K
TELA icon
162
TELA Bio
TELA
$41.5M
$195K 0.02%
+16,990
New +$152K
HNRG icon
163
Hallador Energy
HNRG
$702M
$195K 0.02%
+19,544
New +$161K
CELC icon
164
Celcuity
CELC
$4.49B
$193K 0.02%
+13,800
New +$141K
VMD icon
165
Viemed Healthcare
VMD
$367M
$193K 0.02%
+25,507
New +$173K
FRGI
166
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
$191K 0.02%
+26,053
New +$174K
VYGR icon
167
Voyager Therapeutics
VYGR
$189M
$191K 0.02%
+31,388
New +$178K
CMPX icon
168
Compass Therapeutics
CMPX
$348M
$191K 0.02%
+38,039
New +$152K
NECB icon
169
Northeast Community Bancorp
NECB
$376M
$191K 0.02%
+12,776
New +$176K
XAIR icon
170
Beyond Air
XAIR
$4.4M
$190K 0.02%
+73
New +$187K
EPM icon
171
Evolution Petroleum
EPM
$125M
$190K 0.02%
+25,146
New +$189K
OPTN
172
DELISTED
OptiNose
OPTN
$190K 0.02%
+6,835
New +$260K
SCPH
173
DELISTED
scPharmaceuticals
SCPH
$189K 0.02%
+26,424
New +$161K
VIGL
174
DELISTED
Vigil Neuroscience
VIGL
$189K 0.02%
+15,092
New +$185K
INFU icon
175
InfuSystem Holdings
INFU
$256M
$188K 0.02%
+21,610
New +$176K

Similar funds

683 Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, 683 Capital Management held 372 positions worth $1.18B, down 8.7% from $1.29B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

683 Capital Management withdrew a net $159M in Q4 2022, closing 64 positions and reducing 44 holdings. Its most notable exit was Lennar Class A, an estimated $41.7M position sold in full.

By sector, the portfolio is most concentrated in Financials at 33% of assets, down from 34% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, 683 Capital Management opened a new position in MasterBrand worth $31M.

  • 683 Capital Management's largest Q4 2022 buy was MasterBrand: 4,100,000 shares worth $31M.
  • 683 Capital Management added most to Capital One in Q4 2022, an estimated $17.7M increase.
  • 683 Capital Management's biggest Q4 2022 reduction was Enova International, cutting an estimated $22.8M.
  • 683 Capital Management fully exited Lennar Class A in Q4 2022, selling an estimated $41.7M.
  • 683 Capital Management's ten largest holdings make up 34% of its $1.18B portfolio in Q4 2022.
  • 683 Capital Management opened 125 new positions and closed 64 in Q4 2022.
  • 683 Capital Management's portfolio value fell 8.7% quarter-over-quarter to $1.18B.

Based on 683 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.